Clinical Trial: A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07736001) titled 'A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs' on July 17.

Brief Summary: Evaluation of the efficacy and safety of Trilaciclib in preventing myelosuppression caused by topoisomerase I inhibitor type ADC drugs

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Tumor Patients

Intervention: DRUG: Trilaciclib and Topoisomerase I inhibitor type ADC drugs

Patients who can use topoisomerase I inhibitor type ADC drugs. Intravenous infusion of Trilaciclib should be admin...